[Place of combined cinnarizine-heptanol acefyllinate in treatment of vertigo and ear buzzing of vascular origin].
D000328:Adult; D000368:Aged; D004357:Drug Synergism; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D002537:Intracranial Arteriosclerosis / Q000150:complications / Q000188:drug therapy*; D007759:Labyrinth Diseases / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014717:Vertigo / Q000188:drug therapy* / Q000209:etiology
D006634:Histamine H1 Antagonists; D014665:Vasodilator Agents
Place d'une association cinnarizine-acefyllinate d'heptanol dans le traitement des vertiges et des bourdonnements d'origine vasculaire.